Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

7,541 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Analyzing tyrosine kinase activity in head and neck cancer by functional kinomics: Identification of hyperactivated Src family kinases as prognostic markers and potential targets.
Bußmann L, Hoffer K, von Bargen CM, Droste C, Lange T, Kemmling J, Schröder-Schwarz J, Vu AT, Akingunsade L, Nollau P, Rangarajan S, de Wijn R, Oetting A, Müller C, Böckelmann LC, Zech HB, Berger JC, Möckelmann N, Busch CJ, Böttcher A, Gatzemeier F, Klinghammer K, Simnica D, Binder M, Struve N, Rieckmann T, Schumacher U, Clauditz TS, Betz CS, Petersen C, Rothkamm K, Münscher A, Kriegs M. Bußmann L, et al. Among authors: muller c. Int J Cancer. 2021 Sep 1;149(5):1166-1180. doi: 10.1002/ijc.33606. Epub 2021 May 7. Int J Cancer. 2021. PMID: 33890294
Preclinical patient-derived modeling of castration-resistant prostate cancer facilitates individualized assessment of homologous recombination repair deficient disease.
Elsesy ME, Oh-Hohenhorst SJ, Oing C, Eckhardt A, Burdak-Rothkamm S, Alawi M, Müller C, Schüller U, Maurer T, von Amsberg G, Petersen C, Rothkamm K, Mansour WY. Elsesy ME, et al. Among authors: muller c. Mol Oncol. 2023 Jun;17(6):1129-1147. doi: 10.1002/1878-0261.13382. Epub 2023 Mar 16. Mol Oncol. 2023. PMID: 36694344 Free PMC article.
Pembrolizumab and trastuzumab in combination with FLOT in the perioperative treatment of HER2-positive, localized esophagogastric adenocarcinoma-a phase II trial of the AIO study group (AIO STO 0321).
Tintelnot J, Stein A, Al-Batran SE, Ettrich T, Götze T, Grün B, Haag GM, Heuer V, Hofheinz RD, Homann N, Bröring TS, Cruz MS, Kurreck A, Lorenzen S, Moosmann N, Müller C, Schuler M, Siegler G, Binder M, Gökkurt E. Tintelnot J, et al. Among authors: muller c. Front Oncol. 2023 Oct 16;13:1272175. doi: 10.3389/fonc.2023.1272175. eCollection 2023. Front Oncol. 2023. PMID: 37909020 Free PMC article.
Evaluation of circulating tumor DNA as a prognostic and predictive biomarker in BRAF V600E mutated colorectal cancer-results from the FIRE-4.5 study.
Klein-Scory S, Baraniskin A, Schmiegel W, Mika T, Schroers R, Held S, Heinrich K, Tougeron D, Modest DP, Schwaner I, Eucker J, Pihusch R, Stauch M, Kaiser F, Kahl C, Karthaus M, Müller C, Burkart C, Stintzing S, Heinemann V. Klein-Scory S, et al. Among authors: muller c. Mol Oncol. 2024 Dec 4. doi: 10.1002/1878-0261.13778. Online ahead of print. Mol Oncol. 2024. PMID: 39630848 Free article.
Evaluation of three diagnostic algorithms to reduce normal scan rates, radiation exposure and costs in patients with suspected chronic coronary syndrome referred for 82Rb-Positron Emission Tomography (82Rb-PET).
Frey SM, Huré G, Leibfarth JP, Thommen K, Amrein ML, Schaefer I, Rumora K, Schneider IG, Caobelli F, Wild D, Haaf P, Mahfoud F, Müller C, Zellweger MJ. Frey SM, et al. Among authors: muller c. Open Heart. 2025 Jan 11;12(1):e003086. doi: 10.1136/openhrt-2024-003086. Open Heart. 2025. PMID: 39800434 Free article.
7,541 results